Transcriptomic profiling of a novel gastric implantation model identifies mechanisms and pathways that drive implantation into explanted human peritoneum
IF 6.4 3区 医学Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Deanna Ng, Karineh Kazazian, Kiera Lee, Yi Qing Lu, Aiman Ali, Karina Pacholczyk, Savtaj Brar, James Conner, Igor Jurisica, Christopher Allan McCulloch, Dae-Kyum Kim, Carol Jane Swallow, Marco Magalhaes
{"title":"Transcriptomic profiling of a novel gastric implantation model identifies mechanisms and pathways that drive implantation into explanted human peritoneum","authors":"Deanna Ng, Karineh Kazazian, Kiera Lee, Yi Qing Lu, Aiman Ali, Karina Pacholczyk, Savtaj Brar, James Conner, Igor Jurisica, Christopher Allan McCulloch, Dae-Kyum Kim, Carol Jane Swallow, Marco Magalhaes","doi":"10.1038/s41417-026-01048-1","DOIUrl":null,"url":null,"abstract":"Epithelial cancers such as stomach and ovarian cancer tend to metastasize to the peritoneum, often leading to intractable disease and poor survival. The mechanisms that enable gastric cancer cells to implant, invade, and survive in the peritoneal niche are poorly understood. We developed a novel human peritoneal explant model using freshly harvested peritoneal tissue samples. GFP-labeled human gastric adenocarcinoma cells (AGS) were co-cultured with the peritoneal samples, and 2% of these cells implanted into the peritoneum. The transcriptomic profile of the implanted AGS cells was compared to AGS cells that failed to implant using RNA sequencing. Differentially expressed genes in implanted AGS cells were enriched for cell adhesion and motility. We functionally validated these genes with CRISPR knockout and identified ADAM12 as a regulator of peritoneal metastasis. ADAM12 KO significantly impaired peritoneal metastasis in vivo and ex vivo and marked disruption of the ITGβ1 interactome in GCa cells. Our approach and the new data identify a distinct peritoneal metastasis gene set that facilitates the implantation and invasion of gastric cancer cells within the peritoneum. Disruption of these pathways with peritoneal-directed therapies has the potential to improve survival in patients with high-risk primary gastric cancer.","PeriodicalId":9577,"journal":{"name":"Cancer gene therapy","volume":"33 8","pages":"931-943"},"PeriodicalIF":6.4000,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer gene therapy","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41417-026-01048-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Epithelial cancers such as stomach and ovarian cancer tend to metastasize to the peritoneum, often leading to intractable disease and poor survival. The mechanisms that enable gastric cancer cells to implant, invade, and survive in the peritoneal niche are poorly understood. We developed a novel human peritoneal explant model using freshly harvested peritoneal tissue samples. GFP-labeled human gastric adenocarcinoma cells (AGS) were co-cultured with the peritoneal samples, and 2% of these cells implanted into the peritoneum. The transcriptomic profile of the implanted AGS cells was compared to AGS cells that failed to implant using RNA sequencing. Differentially expressed genes in implanted AGS cells were enriched for cell adhesion and motility. We functionally validated these genes with CRISPR knockout and identified ADAM12 as a regulator of peritoneal metastasis. ADAM12 KO significantly impaired peritoneal metastasis in vivo and ex vivo and marked disruption of the ITGβ1 interactome in GCa cells. Our approach and the new data identify a distinct peritoneal metastasis gene set that facilitates the implantation and invasion of gastric cancer cells within the peritoneum. Disruption of these pathways with peritoneal-directed therapies has the potential to improve survival in patients with high-risk primary gastric cancer.
期刊介绍:
Cancer Gene Therapy is the essential gene and cellular therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene and cellular therapies for cancer. The journal publishes original laboratory and clinical research papers, case reports and review articles. Publication topics include RNAi approaches, drug resistance, hematopoietic progenitor cell gene transfer, cancer stem cells, cellular therapies, homologous recombination, ribozyme technology, antisense technology, tumor immunotherapy and tumor suppressors, translational research, cancer therapy, gene delivery systems (viral and non-viral), anti-gene therapy (antisense, siRNA & ribozymes), apoptosis; mechanisms and therapies, vaccine development, immunology and immunotherapy, DNA synthesis and repair.
Cancer Gene Therapy publishes the results of laboratory investigations, preclinical studies, and clinical trials in the field of gene transfer/gene therapy and cellular therapies as applied to cancer research. Types of articles published include original research articles; case reports; brief communications; review articles in the main fields of drug resistance/sensitivity, gene therapy, cellular therapy, tumor suppressor and anti-oncogene therapy, cytokine/tumor immunotherapy, etc.; industry perspectives; and letters to the editor.